Results: The patients received 2-9 cycles (median 3) of the therapy. Eight patients had more than 50% decrease from their baseline PSA levels during the therapy, for a response rate of 42%; 3 of 9 patients had more than 90% decrease. The median time to disease progression was 3.6 months (1.9-15.3), with median survival of 10.4 months (3.6-42.5). Major toxicities included grade 3 or 4 neutropenia in 4 patients (21.1%). Conclusion: The combination therapy of intravenous docetaxel, oral etoposide, and oral estramustine phosphate was effective and tolerable in patients with HRPC. MP-08.10 The relationship between Charlson score and clinical unilateral T3a prostate cancer Hsu CY 1 , Joniau S 1 , Oyen R 2 , Roskams T 3 , van Poppel H 1 1 Departments of Urology, 2 Radiology and 3 Pathology, University Hospital Leu- ven, Leuven, Belgium Objective: The Charlson index contains 19 categories of comorbidity, which are pri- marily defined using ICD-9-CM diagnoses codes. The overall comorbidity score re- flects the cumulative increased likelihood of one-year mortality; a higher score has a more severe correlation with morbidity. The purpose of this study is to investigate the relationship between the outcomes and Charlson score in patients with clinical uni- lateral T3a prostate cancer. Patients & Methods: Two hundred pa- tients with clinical unilateral T3a prostate cancer detected by digital rectal examina- tion (DRE) underwent RP and bilateral pelvic lymphadenectomy between 1987 and 2004 at our institution. No patient received ADT or RT before RP, while all patients had negative finding on both con- trast enhanced computed tomography of the pelvis and bone scan. The patients were categorized into 3 subgroups accord- ing to the Chlarson score at surgery: group 1: Charlson score 0; group 2: Charl- son score 1; and group 3: Charlson score 2. Cox proportional hazard analysis and Kaplan-Meier method were used to ana- lyze biochemical progression free survival (BPFS), clinical progression free survival (CPFS), cancer specific survival (CSS) and overall survival (OS). Results: The mean follow-up was 70.6 months (range 7 to 177). The mean age was 63.3 years (range 41 to 79). Charlson score 0 was found in 110 patients, Charl- son score 1 in 69 and 2 in 21 patients. Preoperative PSA, node status, margin sta- tus and pathological stage did not differ significantly between all subgroups. Only age was significantly different. In the Cox proportional hazard regression analysis, Charlson score was not a significant pre- dictor in BPFS and CPFS. In the Kaplan- Meier analysis, there were no significant differences between Charlson score groups in all survival outcomes (all p 0.05). The projected 5-year overall sur- vival rates in Charlson group 1, 2 and 3 were 96.1%, 94.4% and 100%, 10-year sur- vival rates were 77.4%, 77.7% and 66.7%. Conclusion: Charlson score does not influ- ence the outcome of patients with clinical locally advanced prostate cancer. However, Charlson score was increased by increasing of patient’s age. RP can be performed in motivated healthy older patients; the pa- tients need to be counseled regarding possi- ble surgery-related side-effects like urinary incontinence and erectile dysfunction, which are age- and comobidity-dependent. MP-08.11 Lymph node collection in radical prostatectomy Arumainayagam N 1 , McPhail S 2 , Ayres B 1 , MacGrath J 1 , Fowler S 3 , Cottier B 4 , Verne J 2 , Gillatt DA 3 1 Bristol Urological Institute; 2 South West Public Health Observatory; 3 British Asso- ciation of Urological Surgeons; 4 National Cancer Surveillance and Analysis Team, Clatterbridge Centre for Oncology, Bris- tol, UK Introduction: This study retrospectively assesses current practice in intra-operative collection of lymph nodes during radical prostatectomy (RP), in relation to pre-opera- tive PSA and Gleason score. Methods: We have linked the cancer registry databases and the clinical database of the Brit- ish Association of Urological Surgeons. The combination of these two sources improves the completeness of the staging and Gleason score of patients undergoing RP. We exam- ined the BAUS complex operations and associ- ated follow-up databases for patients undergo- ing RP from 2004 to 2005. Results: 2706 patients underwent RP, with follow-up records existing for 1988. Nodes were collected in approximately a third of procedures (943/2706). Table 1. MP-08.11 No lymph nodes taken n  1763 Lymph nodes taken n  943 Mean PSA (95% CI) 9.35 (+/- 0.35) 7.21 (+/- 0.24) Mean Gleason Score (95% CI) 6.44 (+/- 0.05) 6.19 (+/- 0.04) While the differences in mean PSA and Gleason score are statistically significant (p  0.01), there is large overlap between the distributions of the Gleason scores and PSA levels between the two groups (mean 0.41 sigma difference between the centres of the distributions). Conclusion: These results suggest inconsis- tency in the clinical practice of intraopera- tive lymph node dissection in radical pros- tatectomies reported in the BAUS dataset. MP-08.12 One single dose of zoledronic acid (Zometa) annually can prevent bone mineral density (BMD) in patients with prostate cancer treated with LHRH: early results of a randomized trial Lekas  1 , Chrisofos M 2 , Fokitis I 1 , Balangas A 3 , Kollias A 3 , Deliveliotis C 2 1 Department of Urology, General Hospi- tal of Nikea, Piraeus, Greece; 2 2 nd De- partment of Urology, Sismanoglio Hospi- tal, School of Medicine, National and Kapodistrian University of Athens, Greece; 3 Department of Urology and Pe- diatric Urology, Ammerland Clinic, West- erstede, Germany Objective: The aim of the present study is to assess the effect of zoledronic acid therapy, received on an annual basis, on the bone density of patients diagnosed with prostate cancer who are treated with LHRH agonist. Material & Method: Our material consisted of 64 patients diagnosed with prostate can- cer who were treated with radical prosta- tectomy and who received an LHRH agonist due to local recurrence of the disease. All patients had nonmetastatic disease at the beginning of the study. Patients were ran- domized according to a table of random numbers (created by using the RANDOM Excel function) into a group of patients re- ceiving zoledronic acid once annually (group A; 34 patients) and into a group where no zoledronic acid was received (group B; 30 patients). Two patients from group A and one from group B were diag- nosed with osteoporosis also one man of group A developed bone metastasis 11 months later. All of them were excluded from the study. Finally, 60 patients (31 from group A and 29 from group B) completed the study. The follow up was performed with measurements of PSA, ALP and mea- surement of lumbar BMD every six (6) months. Results: In men of group A an increase in lumbar BMD was found [mean 2.9, stan- dard deviation (SD) 0.7]. In group B a decrease in BMD was observed [mean 2.1 MODERATED POSTER SESSIONS 80 UROLOGY 70 (Supplment 3A), September 2007